What is HC Wainwright’s Forecast for REGENXBIO Q1 Earnings?

REGENXBIO Inc. (NASDAQ:RGNX) – HC Wainwright upped their Q1 2025 earnings estimates for shares of REGENXBIO in a research note issued on Monday, March 17th. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will earn ($1.21) per share for the quarter, up from their prior forecast of ($1.35). HC Wainwright currently has a “Buy” rating and a $34.00 target price on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO’s Q2 2025 earnings at ($1.20) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.19) EPS and FY2025 earnings at ($4.80) EPS.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million.

Other equities research analysts have also issued research reports about the company. Morgan Stanley increased their target price on REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, March 14th. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Friday, March 14th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $33.88.

REGENXBIO Trading Up 11.4 %

Shares of NASDAQ RGNX opened at $7.80 on Wednesday. The stock has a fifty day moving average price of $7.28 and a 200 day moving average price of $8.94. REGENXBIO has a 12-month low of $5.62 and a 12-month high of $23.14. The company has a market cap of $386.45 million, a P/E ratio of -1.55 and a beta of 1.35.

Institutional Investors Weigh In On REGENXBIO

A number of institutional investors have recently modified their holdings of RGNX. Redmile Group LLC increased its holdings in REGENXBIO by 7.1% in the third quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock valued at $51,327,000 after buying an additional 323,100 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of REGENXBIO by 67.0% during the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock valued at $31,975,000 after acquiring an additional 1,659,206 shares in the last quarter. Millennium Management LLC lifted its stake in REGENXBIO by 406.3% during the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company’s stock worth $10,222,000 after purchasing an additional 1,061,187 shares during the last quarter. Balyasny Asset Management L.P. lifted its stake in REGENXBIO by 6.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company’s stock worth $9,176,000 after purchasing an additional 66,993 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in REGENXBIO by 1.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company’s stock worth $9,054,000 after purchasing an additional 21,234 shares during the period. Institutional investors and hedge funds own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.